51
|
Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-75. [PMID: 22326955 PMCID: PMC3287235 DOI: 10.1172/jci61226] [Citation(s) in RCA: 185] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Accepted: 01/04/2012] [Indexed: 02/06/2023] Open
Abstract
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2; also known as HER-2/neu), is indicated for the treatment of women with either early stage or metastatic HER2(+) breast cancer. It kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Strategies that enhance the activity of ADCC effectors, including NK cells, may improve the efficacy of trastuzumab. Here, we have shown that upon encountering trastuzumab-coated, HER2-overexpressing breast cancer cells, human NK cells become activated and express the costimulatory receptor CD137. CD137 activation, which was dependent on NK cell expression of the FcγRIII receptor, occurred both in vitro and in the peripheral blood of women with HER2-expressing breast cancer after trastuzumab treatment. Stimulation of trastuzumab-activated human NK cells with an agonistic mAb specific for CD137 killed breast cancer cells (including an intrinsically trastuzumab-resistant cell line) more efficiently both in vitro and in vivo in xenotransplant models of human breast cancer, including one using a human primary breast tumor. The enhanced cytotoxicity was restricted to antibody-coated tumor cells. This sequential antibody strategy, combining a tumor-targeting antibody with a second antibody that activates the host innate immune system, may improve the therapeutic effects of antibodies against breast cancer and other HER2-expressing tumors.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antineoplastic Agents/administration & dosage
- Breast Neoplasms/drug therapy
- Drug Synergism
- Female
- Humans
- Killer Cells, Natural/cytology
- Mammary Neoplasms, Animal/drug therapy
- Mice
- Mice, Nude
- Mice, SCID
- Neoplasm Transplantation
- Transplantation, Heterologous
- Trastuzumab
- Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
- Tumor Necrosis Factor Receptor Superfamily, Member 9/metabolism
Collapse
Affiliation(s)
- Holbrook E. Kohrt
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Roch Houot
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Kipp Weiskopf
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Matthew J. Goldstein
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Ferenc Scheeren
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Debra Czerwinski
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - A. Dimitrios Colevas
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Wen-Kai Weng
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Michael F. Clarke
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Robert W. Carlson
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Frank E. Stockdale
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Joseph A. Mollick
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Lieping Chen
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| | - Ronald Levy
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Service d’Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
INSERM U917, Université de Rennes 1, Rennes, France.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
| |
Collapse
|
54
|
Yu Y, Luo J, Mitra A, Chang S, Tian F, Zhang H, Yuan P, Zhou H, Song J. Temporal transcriptome changes induced by MDV in Marek's disease-resistant and -susceptible inbred chickens. BMC Genomics 2011; 12:501. [PMID: 21992110 PMCID: PMC3269463 DOI: 10.1186/1471-2164-12-501] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2011] [Accepted: 10/12/2011] [Indexed: 11/10/2022] Open
Abstract
Background Marek's disease (MD) is a lymphoproliferative disease in chickens caused by Marek's disease virus (MDV) and characterized by T cell lymphoma and infiltration of lymphoid cells into various organs such as liver, spleen, peripheral nerves and muscle. Resistance to MD and disease risk have long been thought to be influenced both by genetic and environmental factors, the combination of which contributes to the observed outcome in an individual. We hypothesize that after MDV infection, genes related to MD-resistance or -susceptibility may exhibit different trends in transcriptional activity in chicken lines having a varying degree of resistance to MD. Results In order to study the mechanisms of resistance and susceptibility to MD, we performed genome-wide temporal expression analysis in spleen tissues from MD-resistant line 63, susceptible line 72 and recombinant congenic strain M (RCS-M) that has a phenotype intermediate between lines 63 and 72 after MDV infection. Three time points of the MDV life cycle in chicken were selected for study: 5 days post infection (dpi), 10dpi and 21dpi, representing the early cytolytic, latent and late cytolytic stages, respectively. We observed similar gene expression profiles at the three time points in line 63 and RCS-M chickens that are both different from line 72. Pathway analysis using Ingenuity Pathway Analysis (IPA) showed that MDV can broadly influence the chickens irrespective of whether they are resistant or susceptible to MD. However, some pathways like cardiac arrhythmia and cardiovascular disease were found to be affected only in line 72; while some networks related to cell-mediated immune response and antigen presentation were enriched only in line 63 and RCS-M. We identified 78 and 30 candidate genes associated with MD resistance, at 10 and 21dpi respectively, by considering genes having the same trend of expression change after MDV infection in lines 63 and RCS-M. On the other hand, by considering genes with the same trend of expression change after MDV infection in lines 72 and RCS-M, we identified 78 and 43 genes at 10 and 21dpi, respectively, which may be associated with MD-susceptibility. Conclusions By testing temporal transcriptome changes using three representative chicken lines with different resistance to MD, we identified 108 candidate genes for MD-resistance and 121 candidate genes for MD-susceptibility over the three time points. Genes included in our resistance or susceptibility genes lists that are also involved in more than 5 biofunctions, such as CD8α, IL8, USP18, and CTLA4, are considered to be important genes involved in MD-resistance or -susceptibility. We were also able to identify several biofunctions related with immune response that we believe play an important role in MD-resistance.
Collapse
Affiliation(s)
- Ying Yu
- Department of Animal & Avian Sciences, University of Maryland, College Park, MD 20742, USA
| | | | | | | | | | | | | | | | | |
Collapse
|